Myriad Genetics Announces Publication of a Prospective Clinical Study of the EndoPredict Test in Women with Early-Stage Breast Cancer | 2020-06-04 |…
Posted: June 5, 2020 at 11:45 pm
SALT LAKE CITY, June 04, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, Myriad” or the Company”), a global leader in molecular diagnostics and precision medicine, today announced the publication of a prospective study demonstrating that the EndoPredict® test predicts which patients with ER+, HER2- early-stage breast cancer will benefit from neoadjuvant therapy. The article titled, The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial,” appeared online in the European Journal of Cancer.
This study demonstrated that the EndoPredict (EP) test predicted response to neoadjuvant chemotherapy or neoadjuvant endocrine therapy in women with ER+, HER2 negative early-stage breast cancer,” said Peter Dubsky, M.D., lead author, speaking on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG). Based on these findings and prior studies, we are confident the EndoPredict test can add valuable information to aid in personalized treatment selection in neoadjuvant therapy and provides an important basis for future design of neoadjuvant clinical trials.”
The primary objective of this prospective study was to test the predictive value of the EndoPredict test regarding tumor response after neoadjuvant chemotherapy (NaCT) or neoadjuvant endocrine therapy (NET) within the ABCSG-34 trial. The analysis included data from 217 women with HR+ breast cancer. Of these, 134 patients were assigned to receive NaCT (eight cycles of anthracycline/taxane) according to aggressive clinico-pathologic tumor features. The remaining 83 patients were clinically identified as having luminal A-like types of breast cancer and were assigned to receive NET (six months of letrozole). The primary endpoint was residual cancer burden RCB0/I (i.e., good tumor response) vs. RCB II/III (i.e., poor tumor response) at time of surgery.
In the neoadjuvant chemotherapy group, 125 patients had high EP scores and nine had a low EP score. The results show that 26.4 percent of those with a high score showed a good tumor response (RCB0/I) to neoadjuvant chemotherapy, while all patients with a low score showed only a poor tumor response (Table 1). In the luminal A” group receiving neoendocrine therapy, 39 patients had a high EP score and 44 had a low EP score. The results show that 27.3 percent of those with a low EndoPredict score and 7.7 percent with a high score achieved excellent tumor response (RCB0/I) to neoendocrine therapy (Table 1).
EndoPredict Low Score
EndoPredict High Score
0.0
%
26.4
%
p=0.0001
In this prospective study, we demonstrated that the EndoPredict test is a useful tool pre-operatively,” said Ralf Kronenwett, M.D., director of International Medical Affairs at Myriad. In two distinct ER-positive, HER2-negative cohorts selected by clinicians to receive neoadjuvant chemotherapy or neoadjuvant endocrine therapy, EndoPredict identified patients with poor neoadjuvant treatment response. Clinicians can use information to determine who might forgo these therapies prior to surgery.”
About EndoPredict EndoPredict is a second-generation, 12-gene molecular prognostic test for patients diagnosed with breast cancer. The test provides vital information that helps clinicians devise personalized treatment plans for their patients. EndoPredict has been validated in more than 4,000 patients with node-negative and node-positive cancer and has been used clinically in more than 20,000 patients. In contrast to first-generation multigene prognostic tests, EndoPredict detects the likelihood of late metastases (i.e., metastasis formation after more than five years) and, therefore, can guide treatment decisions regarding the need for chemotherapy, as well as extended anti-hormonal therapy. Accordingly, therapy decisions backed by EndoPredict confer a high level of diagnostic safety. For more information, please visit: http://www.endopredict.com.
About Myriad Genetics Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.
Safe Harbor Statement This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the EndoPredict test adding valuable information to aid in personalized treatment selection in neoadjuvant therapy and providing an important basis for future design of neoadjuvant clinical trials; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers’ reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Int’l, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.
- Denial of hormones is more than women should bear - The Medical Republic - February 23rd, 2024
- Katy couple discovers benefits of hormone replacement therapy - FOX 26 Houston - February 13th, 2024
- Gender-affirming care clinic in Thunder Bay, Ont., closes, leaving patients with limited options - CBC.ca - February 5th, 2024
- What It Means That Lisa Rinna Is On HRT For Menopause - Women's Health - January 11th, 2024
- Lisa Rinna Was Initially 'Very Scared' of Hormone Replacement Therapy. She Isn't the Only One - The Messenger - January 11th, 2024
- MrBeast's Kris Tyson Shares Before and After Photos Following 1 Year of Hormone Replacement Therapy - PEOPLE - January 11th, 2024
- Lisa Rinna Was 'Really Scared' to Undergo Hormone Replacement Therapy for Menopause Symptoms: 'I Haven't ... - Yahoo Entertainment - January 11th, 2024
- Kris Tyson Before And After HRT Pictures - BuzzFeed - January 11th, 2024
- Hormone replacement therapy and early menopause tied heightened risk of rheumatoid arthritis - Medical Dialogues - January 11th, 2024
- Open for Business: Alpine Wellness opens new clinic for integrative medicine and hormone health - KOLO - January 3rd, 2024
- Is Hormone Replacement Therapy Right for You? What to Know - Motherly Inc. - January 3rd, 2024
- Easy as visiting the GP: Doctors push for accessible hormone treatment as childrens waitlist swells - The Age - January 3rd, 2024
- How to Balance Hormones: 11 Nondrug and Drug Options - Verywell Health - December 25th, 2023
- Hormone Replacement Therapy Market Poised for a Remarkable US$ 23,729.6 Million Valuation by 2034, Fueled by a ... - Yahoo Finance - December 25th, 2023
- Home - CHS Hormone - December 6th, 2023
- My teenage son was indoctrinated by the trans cult from the classroom to the clinic: Mother left 'grieving' fo - Daily Mail - November 27th, 2023
- Hormone Evaluation and Replacement Therapy | Amen Clinics - November 2nd, 2023
- Depression can hit hard during the winter months, here's how to prevent it - NewsCenterMaine.com WCSH-WLBZ - October 16th, 2023
- As a study finds a stable weight is key to living longer, a leading nutritionist's guide on how to... Escape t - Daily Mail - October 16th, 2023
- I worked at the Tavistock gender clinic. Closing it was the right move - The Dallas Morning News - April 26th, 2023
- What causes hormonal imbalance and how to avoid it? - GMA News Online - March 23rd, 2023
- Thyroid Hormone: What It Is & Function - Cleveland Clinic - December 20th, 2022
- Menopause - Symptoms and causes - Mayo Clinic - December 20th, 2022
- Human Chorionic Gonadotropin: Hormone, Purpose & Levels - Cleveland Clinic - December 20th, 2022
- Polycystic ovary syndrome (PCOS) - Symptoms and causes - Mayo Clinic - December 20th, 2022
- Hypothyroidism: Symptoms, Causes, Treatment & Medication - Cleveland Clinic - December 20th, 2022
- Postpartum depression - Symptoms and causes - Mayo Clinic - December 20th, 2022
- Let's Talk Sex | Unpacking the Mystery of PCOS: Causes, Symptoms and Treatments - News18 - December 20th, 2022
- Masculinizing hormone therapy - Mayo Clinic - October 16th, 2022
- Human Growth Hormone (hGH) - Cleveland Clinic - October 16th, 2022
- Chronic stress puts your health at risk - Mayo Clinic - October 16th, 2022
- Menstrual Migraines (Hormone Headaches) - Cleveland Clinic - October 16th, 2022
- Acromegaly: What It Is, Causes, Symptoms & Treatment - Cleveland Clinic - October 16th, 2022
- Hormone Therapy and Shoulder Pain During Menopause - Healthline - October 16th, 2022
- CHOICES Reproductive Health clinic now open in Carbondale - WSIL TV - October 16th, 2022
- Helping Reduce Your Risk of Breast Cancer ThedaCare - ThedaCare - October 16th, 2022
- HIV patients abused and humiliated - News24 - October 16th, 2022
- Recommended Approaches to Treatment for Early-Stage HER2+ Breast Cancer - Targeted Oncology - October 16th, 2022
- Diabetes and the gut: How a bacterial protein may impact insulin - Medical News Today - October 16th, 2022
- TUCKER CARLSON: The Democratic Party is replacing parents with itself - Fox News - October 16th, 2022
- 'You will get your heart broken. Not might, will.': Foster mom shares heartwarming adoption after infertility, heartbreak - Love What Matters - October 16th, 2022
- Everything You Need To Know About Hormone Replacement Therapy - Health Digest - August 11th, 2022
- What is hormone therapy for breast cancer? - MD Anderson - August 11th, 2022
- Brevard LGBTQ clinic responds to proposed restrictions on trans healthcare - Florida Today - August 11th, 2022
- Aldosterone, a hormone that prevents dehydration, is linked to worsening kidney disease, study suggests - STAT - August 11th, 2022
- 8 reasons why you wake up tired, and how to fix it - WDJT - August 11th, 2022
- What We Learned About Steve Jobs' Health After His Death - Health Digest - August 11th, 2022
- Hormonal Acne: Causes, Treatment, And How To Prevent It - Women's Health - August 11th, 2022
- Bastion Health Announces the addition of Dr. Justin Houman as Medical Director - PR Web - August 11th, 2022
- Lanta Flat Belly Shake Reviews - Really Effective for Weight Loss? Urgent Customer WARNING - Outlook India - August 11th, 2022
- Some Women Turn to Self-Managed Abortion as Access Recedes - The New York Times - August 11th, 2022
- Can I Still Get the Abortion Pill? Everything to Know - CNET - August 11th, 2022
- Why You Need To Stop Using Your Android Phone Before Going To Sleep - SlashGear - August 11th, 2022
- What the Tavistock clinics closure means for the trans debate - The Week UK - August 3rd, 2022
- India's First Trans Trainee Pilot Adam Harry's Case That Led DGCA To Work On Policy For Trans Pilots - Outlook India - August 3rd, 2022
- 6 Medical Conditions That Can Cause You to Gain Weight - SciTechDaily - August 3rd, 2022
- Guideline change removes 'demeaning' barrier to hormone therapy - Stuff - August 3rd, 2022
- Injectable HIV Prevention Better Than Pills in Two Trials - Medscape - August 3rd, 2022
- I Tested My Stress and It Was Through the RoofHeres the Expert-Backed Plan Thats Getting Me Through It - Well+Good - August 3rd, 2022
- 7 home remedies for crows feet to keep wrinkles and fine lines at bay - Health shots - August 3rd, 2022
- The Real Effects Owning A Pet Has On Your Body - Health Digest - August 3rd, 2022
- Lets Talk About Misoprostolthe Original Abortion Pill - Ms. Magazine - August 3rd, 2022
- This Period-Tracking Method Will Protect Your Privacy Better Than an App - CNET - August 3rd, 2022
- The circulating 70 kDa heat shock protein (HSPA1A) level is a potential biomarker for breast carcinoma and its progression | Scientific Reports -... - August 3rd, 2022
- Hormone Therapy for Menopause Symptoms - Cleveland Clinic - June 28th, 2022
- Hormone therapy for breast cancer - Mayo Clinic - June 28th, 2022
- Gonadotropin-Releasing Hormone (GnRH): Purpose & Testing - June 28th, 2022
- Family Tree Clinic has broadened its scope of services and its regional impact by helping transgender people get the hormone care they need - Sahan... - June 28th, 2022
- Hot Flashes From Hormone Therapy, Poorer Outcomes in Breast Cancer - Medscape - June 28th, 2022
- Smartphone use increases urination at night: nutritionist - - June 28th, 2022
- How To Track Your Ovulation Most Accurately, According To Ob-Gyns - Women's Health - June 28th, 2022
- Anti-Abortion Centers Find Pregnant Teens Online, Then Save Their Data - Bloomberg - June 28th, 2022
- The most common birth control methods and how effective they are at preventing pregnancy - Yahoo Life - June 28th, 2022
- The Journey To Be Me: The heartbreak, hope and courage of a Maine transgender child - Maine Public - June 18th, 2022
- How To Reintroduce Lactation After Stopping Breastfeeding - Health Essentials from Cleveland Clinic - June 18th, 2022
- Medication abortions are easy to access in Oregon, but how do they work? - Oregon Public Broadcasting - June 18th, 2022
- How does an IUD work and how long does it last? - Reviewed - June 18th, 2022
- Men's Wellness: Being proactive, annual care key to maintaining health - LimaOhio.com - June 18th, 2022
- Hormone-Replacement Therapy Is Life-Changing: What to Consider Before Getting Started - POPSUGAR - June 9th, 2022
- Do You Need Hormone Testing? - Health Essentials from Cleveland Clinic - June 9th, 2022